Brind.

ABR is tracking Gilead Sciences stock based on analyst recommendations.

1 report, 0 independent Updated Jul 9

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

ABR Gilead Sciences

Keep exploring

The entities involved

ABR
Czech company
- W.P. Carey holds a large portfolio in the United States and Western Europe, with top 10 tenants accounting for 19.4% of ABR.Sun 05:51
- ABR is calculated based on analyst recommendations, using Zacks Rank to categorize stocks for price performance.Sun 04:48
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Sun 22:40
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.Sat 01:51

Related events

Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.Sep 10
Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.Sep 22

Coverage

Newest first; wire copies grouped

Jul 9Unknown outlet